Hydroxy Chloroquine and Covid in RA Patients

Study Overview
=================
Brief Summary
-----------------
evaluation of the clinical course of COVID-19 in a cohort of patients with rheumatoid arthritis treated with or without hydroxychloroquine.

Detailed Description
-----------------
Study settings & sample: This is an observational, retrospective -case-control, single-center study. This study will include patients who meet the inclusion criteria followed in the Department of Rheumatology and Rehabilitation, Tanta University Hospital, Tanta, Egypt. Data will be taken from the medical records of patients with rheumatoid arthritis in the outpatient clinic of the Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. All patients will sign the informed consent form authorizing the collection of these data. Group classification A) Patients with rheumatoid arthritis using hydroxychloroquine as a part of their treatment regimen. b) Patients with rheumatoid arthritis not using hydroxychloroquine as a part of their treatment regimen. Data will be collected and analyzed from patient medical records. It will include the following: Epidemiologic, demographic, and clinical data. Severity of rheumatoid arthritis. Rheumatoid arthritis activity state using the Clinical Disease Activity Index Dose and duration of hydroxychloroquine Need for hospitalization, length of hospital stay, and ICU admission including the need for mechanical ventilation. Duration from the start of symptoms until clinical cure. Severity of COVID-19 disease according to the World Health Organization interim guidance Prognosis. Laboratory investigations and imaging: Complete blood count. Renal and liver function tests. Random blood sugar. Lactate dehydrogenase, D-dimer. Serum ferritin, C-reactive protein, Chest radiographs or CT scan

Official Title
-----------------
Clinical Course of COVID-19 in Patients With Rheumatoid Arthritis Treated With or Without Hydroxychloroquine: a Case-control Study

Conditions
-----------------
COVID

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with rheumatoid arthritis superinfected with Covid-19 Exclusion Criteria: Insufficient data are available in the medical record.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental<br>Patient with rheumatoid arthritis using hydroxychloroquine as a part of their treatment regimen. | |
| Active Comparator<br>Patient with rheumatoid arthritis not using hydroxychloroquine as a part of their treatment regimen | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients in need for hospitalization | Estimate number of patients in need for hospitalization | through study completion an average 12 weeks | 
| Length of hospitalization and ICU admission | Calculate the number of days that the patients stayed at the hospital and how many patients admitted to ICU | through study completion an average 12 weeks | 
| The need for mechanical ventilation | Calculate the number of patients who received mechanical ventilation | through study completion an average 12 weeks | 
| Severity of COVID-19 disease | WHO clinical management Covid19 interim guidance disease severity Algorithm | through study completion an average 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Covid-19, Hydroxy chloroquine, Rheumatoid